Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “prostate-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 133
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 133 pipeline programs matching "prostate-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

133 results for “prostate-cancer” Back to intelligence hub

Search results

Page 4 of 6
  1. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial
  2. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial
  3. SX-682

    United Therapeutics Europe Ltd

    Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial
  4. Selinexor

    Karyopharm Therapeutics Inc

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial
  5. Steroids switch

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule completed

    1 trial
  6. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial
  7. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial
  8. Testosterone Enanthate 100 MG/ML Injectable Solution

    Hospital Authority, Hong Kong

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial
  9. Testosterone cypionate

    United Therapeutics Europe Ltd

    Castration Resistant Metastatic Prostate Cancer

    phase 2 small molecule completed

    1 trial
  10. Zoladex

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial
  11. aglatimagene besadenovec

    Candel Therapeutics

    Prostate Cancer

    phase 2 mab active

    1 trial
  12. aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer Patients Treated by Radiotherapy

    phase 2 mab active

    1 trial
  13. 177Lu-DOTA-TLX591

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 mab completed

    1 trial
  14. 2mg INO-5150 and electroporation device CELLECTRA®-5P

    INOVIO PHARMACEUTICALS, INC.

    Prostate Cancer

    phase 1 mab completed

    1 trial
  15. 64Cu-DOTA-TLX592

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 small molecule completed

    1 trial
  16. 68Ga-AAZTA-NI-093

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 1 small molecule active

    1 trial
  17. 68Ga-PSMA-11

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 1 small molecule active

    1 trial
  18. 89Zr-DFO-YS5

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 small molecule active

    1 trial
  19. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial
  20. AMG 509

    BEONE MEDICINES AUS PTY LTD

    Prostate Cancer

    phase 1 small molecule active

    1 trial
  21. AZD3514

    AstraZeneca

    Prostate Cancer

    phase 1 small molecule completed

    1 trial
  22. BMS-641988 (AR#2)

    Bristol-Myers Squibb

    Prostate Cancer

    phase 1 small molecule completed

    1 trial
  23. BPX-601

    Regeneron UK Limited

    Prostate Cancer

    phase 1 gene therapy active

    1 trial
  24. BPX-601

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 1 mab terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.